priors.science/reviews/heart-failure-management

Heart Failure Management

The current evidence on 20 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty: how firmly the literature supports the claim as stated.

22claims tracked
20assessed
274primary papers reviewed
26 Oct 2026latest evidence review
Overall grades reviewedby 1 independent expert · Sep 2026 · release 2026-q4
6 Established · 11 Likely · 1 Uncertain · 2 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
SGLT2 inhibitors reduce mortality in heart failure with reduced ejection fractionPharmEstablished91%12
SGLT2 inhibitors reduce heart failure hospitalisation in heart failure with preserved ejection fractionHFPEFEstablished90%12
Sacubitril/valsartan does not reduce mortality in heart failure with preserved ejection fractionHFPEFEstablished90%10
Beta-blockers reduce mortality in heart failure with reduced ejection fractionPharmEstablished90%13
Vericiguat neutral for primary endpoint in stable heart failure with reduced ejection fractionNovelEstablished87%24
Mineralocorticoid receptor antagonist reduces mortality in heart failure with reduced ejection fractionPharmEstablished86%11
Cardiac resynchronisation therapy reduces mortality in heart failure with reduced ejection fraction and left bundle branch blockCRTLong-standingLikely84%24
Angiotensin receptor-neprilysin inhibitor reduces mortality versus ACE inhibitor or angiotensin receptor blocker in heart failure with reduced ejection fractionPharmLikely84%10thin basis
Acetazolamide improves decongestion in acute decompensated heart failureAdhfLikely83%12
Finerenone reduces heart failure events in heart failure with mildly reduced or preserved ejection fractionHFPEFEarly evidenceLikely82%22
Vericiguat reduces events in worsening heart failure with reduced ejection fractionNovelLikely82%13
HeartMate 3 superior to axial-flow left ventricular assist devicesLvadLikely80%15
Left ventricular assist device destination therapy improves survival in end-stage heart failureLvadLikely80%18
Primary prevention implantable cardioverter-defibrillator reduces sudden cardiac deathIcdLikely76%13
Intravenous iron does not reduce all-cause mortality in heart failureIronLikely74%12thin basis
SGLT2 inhibitors improve outcomes in acute decompensated heart failureAdhfLikely72%11
Intravenous iron reduces heart failure hospitalisationIronLikely71%9
Left bundle branch pacing achieves superior resynchronisation versus conventional biventricular cardiac resynchronisation therapyCRTUncertain52%21
Implantable cardioverter-defibrillator reduces all-cause mortality in the contemporary eraIcdDoubtful45%10thin basis
Cardiac resynchronisation therapy with defibrillator and with pacemaker have similar all-cause mortalityCRTLong-standingDoubtful40%18
Track Heart Failure Management.
These claims are re-checked against new research as it is published. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing: what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it. Confidently false as stated.
A standing changes only when the score moves past a boundary by more than 4 points, the re-scoring noise floor; a score within 4 points of a boundary keeps its previous standing.
Where the evidence sits in time
Early evidenceMost of this evidence is from the last two years.
Long-standingMost of this evidence is older than the rest of this field.